Physician profile
Gary Lee Badzinski
NPI 1821094327
$2,239.65
in general payments reported to CMS, 2019-2025
9 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2021: $11.75 · 2022: $173 · 2023: $433 · 2024: $171 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Travel and Lodging: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.05 |
| Travel and Lodging | $307.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $422.16 | 2019-2024 | Amplatzer, Perclose Prostyle |
| Stryker Corporation | $411.17 | 2025 | Artix Mt, Flowtriever, Clottriever Bold Catheter |
| Medtronic, INC. | $372.42 | 2023 | Micra |
| Abiomed | $321.90 | 2022-2025 | Impella |
| Shockwave Medical, INC | $305.63 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $271.90 | 2019-2025 | Enhance Transcarotid Peripheral Access Kit, Enroute Transcarotid Neuroprotection System, Watchman Access System |
| Angiodynamics, INC. | $105.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.66 | 2023 | |
| Asahi Intecc USA, INC. | $13.43 | 2024 | Peripheral Vascular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Badzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.